These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 23683592

  • 21. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
    El-Azab AS, Al-Dhfyan A, Abdel-Aziz AA, Abou-Zeid LA, Alkahtani HM, Al-Obaid AM, Al-Gendy MA.
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
    [Abstract] [Full Text] [Related]

  • 22. Design, synthesis and biological activities of novel oxazolo[4,5-g]quinazolin-2(1H)-one derivatives as EGFR inhibitors.
    Yin S, Zhou L, Lin J, Xue L, Zhang C.
    Eur J Med Chem; 2015 Aug 28; 101():462-75. PubMed ID: 26188620
    [Abstract] [Full Text] [Related]

  • 23. Synthesis, biological evaluation and molecular modeling study of new (1,2,4-triazole or 1,3,4-thiadiazole)-methylthio-derivatives of quinazolin-4(3H)-one as DHFR inhibitors.
    El-Gazzar YI, Georgey HH, El-Messery SM, Ewida HA, Hassan GS, Raafat MM, Ewida MA, El-Subbagh HI.
    Bioorg Chem; 2017 Jun 28; 72():282-292. PubMed ID: 28499189
    [Abstract] [Full Text] [Related]

  • 24. 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1).
    Penthala NR, Ketkar A, Sekhar KR, Freeman ML, Eoff RL, Balusu R, Crooks PA.
    Bioorg Med Chem; 2015 Nov 15; 23(22):7226-33. PubMed ID: 26602084
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
    Huang XF, Lu X, Zhang Y, Song GQ, He QL, Li QS, Yang XH, Wei Y, Zhu HL.
    Bioorg Med Chem; 2012 Aug 15; 20(16):4895-900. PubMed ID: 22819191
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD, Fang F, Li JR, Du QR, Sun J, Gong HB, Zhu HL.
    Bioorg Med Chem Lett; 2012 Sep 15; 22(18):5870-5. PubMed ID: 22901387
    [Abstract] [Full Text] [Related]

  • 34. Synthesis, and docking studies of some fused-quinazolines and quinazolines carrying biological active isatin moiety as cell-cycle inhibitors of breast cancer cell lines.
    Radwan AA, Alanazi FK, Al-Dhfyan A.
    Drug Res (Stuttg); 2013 Mar 15; 63(3):129-36. PubMed ID: 23444171
    [Abstract] [Full Text] [Related]

  • 35. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
    Xu YY, Li SN, Yu GJ, Hu QH, Li HQ.
    Bioorg Med Chem; 2013 Oct 01; 21(19):6084-91. PubMed ID: 23962660
    [Abstract] [Full Text] [Related]

  • 36. Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran-pyrazole derivatives as anticancer agents.
    Abd El-Karim SS, Anwar MM, Mohamed NA, Nasr T, Elseginy SA.
    Bioorg Chem; 2015 Dec 01; 63():1-12. PubMed ID: 26368040
    [Abstract] [Full Text] [Related]

  • 37. Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents.
    Jiang N, Zhai X, Zhao Y, Liu Y, Qi B, Tao H, Gong P.
    Eur J Med Chem; 2012 Aug 01; 54():534-41. PubMed ID: 22727449
    [Abstract] [Full Text] [Related]

  • 38. Synthesis and evaluation of some new pyrazoline substituted benzenesulfonylureas as potential antiproliferative agents.
    Rathore P, Yaseen S, Ovais S, Bashir R, Yaseen R, Hameed AD, Samim M, Gupta R, Hussain F, Javed K.
    Bioorg Med Chem Lett; 2014 Apr 01; 24(7):1685-91. PubMed ID: 24630557
    [Abstract] [Full Text] [Related]

  • 39. Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity.
    Li HQ, Li DD, Lu X, Xu YY, Zhu HL.
    Bioorg Med Chem; 2012 Jan 01; 20(1):317-23. PubMed ID: 22112541
    [Abstract] [Full Text] [Related]

  • 40. Sulphonamido-quinoxalines: search for anticancer agent.
    Ingle R, Marathe R, Magar D, Patel HM, Surana SJ.
    Eur J Med Chem; 2013 Jul 01; 65():168-86. PubMed ID: 23708011
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.